hyperphosphataemia love

hyperphosphataemia

Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun Alternative form of hyperphosphatemia.

Etymologies

Sorry, no etymologies found.

Support

Help support Wordnik (and make this page ad-free) by adopting the word hyperphosphataemia.

Examples

  • Renvelais also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus >

    unknown title 2009

  • The benefits with Renvelaare its phosphate-lowering effect for controlling hyperphosphataemia in adult patients on dialysis and in adult patients with chronic kidney disease not on dialysis with serum phosphorus >

    unknown title 2009

  • Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus >

    unknown title 2009

  • (CHMP) adopted a positive opinion, ** recommending to grant a marketing authorisation for the medicinal product Renvela, 800mg film-coated tablets and 1.6 and 2.4 g powder for oral suspension, intended for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.

    unknown title 2009

  • Notes to Editors ABOUT FOSRENOL (R) (lanthanum carbonate) FOSRENOL is indicated: - In the EU as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis.

    unknown title 2009

  • - FOSRENOL (R) (lanthanum carbonate) Now Approved in the EU to Treat hyperphosphataemia

    unknown title 2009

  • * Renvela (sevelamer carbonate), from people) Europe B.V., indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis, and for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus >

    Forbes.com: News 2009

  • The approved indication is: "Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.

    unknown title 2009

  • SHPGY), the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL (R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1. 78mmol/L (5. 5mg/dL).

    unknown title 2009

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.